Stroke is one of the most common diseases worldwide. A current focus of res
earch is to find neuroprotectants that can be given during acute stroke. On
e specific target is to find antagonists of the N-methyl-D-aspartate (NMDA)
receptor in an attempt to limit glutamate associated neurotoxicity. Xenon
has recently been found to be an NMDA receptor antagonist. I suggest that x
enon be considered as a neuroprotectant in acute stroke, and discuss method
s of testing this proposal. (C) 2001 Harcourt Publishers Ltd.